News summary
[Nuowizanmyjackpotslots&casino: Luciferase reporter gene testing reagent helps develop GLP-1RA drugs for "weight loss"] Securities Times e Company News, Novizan today's official Weibo news that GLP-1 drugs rely on their excellencemyjackpotslots&casinoThe clinical data and efficacy of new obesity drugs have become the focus of the research and development of new obesity drugs. GLP-1RA drugmyjackpotslots&casino.myjackpotslots&casino..
Newsletter text
[Novizan: Luciferase reporter gene detection reagent helps develop GLP-1RA drugs for "weight-loss drugs"] Securities Times e Company News, Novizan announced today that GLP-1 drugs, with their excellent clinical data and efficacy, have become the focus of the research and development of new obesity drugs. Activity testing of GLP-1RA drugs is a key part of the drug development process. Currently, the mainstream method is the luciferase reporter gene method. Novizan can provide detection reagents and corresponding solutions to accelerate the progress of GLP-1RA drug research and development. Currently, it has supplied multiple GLP-1RA drug research and development projects that have entered the clinical stage.